Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Friday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of OGEN stock opened at $0.31 on Friday. The business has a 50 day simple moving average of $0.34 and a 200 day simple moving average of $0.55. The firm has a market capitalization of $3.77 million, a price-to-earnings ratio of -0.04 and a beta of 0.40. Oragenics has a 12-month low of $0.25 and a 12-month high of $4.00.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.